8-K: PepGen Announces Presentations on DMD and DM1 Programs at World Muscle Society Congress

PepGen will present clinical and preclinical data on its Duchenne muscular dystrophy and myotonic dystrophy type 1 programs at the 29th Annual Congress of the World Muscle Society.

Summary

• PepGen announced it will be presenting at the 29th Annual Congress of the World Muscle Society (WMS) in Prague from October 8-12, 2024.
• The company will deliver a short oral presentation and five posters covering their Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs.
• The presentations will include data from the CONNECT1-EDO51 trial, which is evaluating PGN-EDO51 for DMD.
• As of October 3, 2024, the data suggests a favorable emerging safety profile for PGN-EDO51, with no serious adverse events reported.
• All treatment-related adverse events have been mild and resolved, with one instance of hypomagnesemia that was resolved with oral supplementation.
• All participants in the study continue as planned, with no discontinuations, dose interruptions, or reductions.
• PepGen's PGN-EDO51 is designed to skip exon 51 of the dystrophin transcript, targeting approximately 13% of DMD patients.
• PGN-EDODM1, PepGen's candidate for DM1, is designed to restore the normal splicing function of MBNL1.
• The FDA has granted PGN-EDO51 Orphan Drug and Rare Pediatric Disease Designations, and PGN-EDODM1 Orphan Drug and Fast Track Designations.

Sentiment

Score: 7

Explanation: The document presents positive safety data and progress in clinical trials, but also includes standard risk disclosures, resulting in a moderately positive sentiment.

Positives

• PGN-EDO51 demonstrates a favorable emerging safety profile with no serious adverse events reported.
• All treatment-related adverse events for PGN-EDO51 were mild and resolved.
• All participants in the PGN-EDO51 study continue as planned, with no discontinuations, dose interruptions, or reductions.
• Both PGN-EDO51 and PGN-EDODM1 have received special designations from the FDA, highlighting their potential to address unmet medical needs.

Negatives

• One patient in the PGN-EDO51 trial experienced hypomagnesemia, although it was resolved with oral supplementation.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks include delays or failures in development activities, incorrect interpretations of study results, and the possibility that the product candidates may not be safe or effective.
• There are also risks related to regulatory interactions, changes in the regulatory framework, and unexpected increases in expenses.
• The company is dependent on third parties for manufacturing, research, and testing.
• There is no guarantee that PGN-EDO51 or any other investigational therapy will successfully complete clinical development or gain regulatory approval.

Future Outlook

The company plans to continue to advance the CONNECT1 study and will make the presentations available on their website after the conference.

Management Comments

• James McArthur, PhD, President and CEO of PepGen, stated that they are pleased to be presenting preclinical and clinical data on their DMD and DM1 programs at the WMS meeting.
• James McArthur, PhD, President and CEO of PepGen, stated that based on the totality of data in both our 5 mg/kg cohort and the ongoing 10 mg/kg cohort in the CONNECT1-EDO51 trial as of October 3, we believe PGN-EDO51 has a favorable emerging safety profile.

Industry Context

This announcement highlights PepGen's progress in developing oligonucleotide therapies for neuromuscular diseases, a field with significant unmet medical needs and growing interest from both pharmaceutical companies and investors.

Comparison to Industry Standards

• The development of exon-skipping therapies for DMD is a competitive area, with companies like Sarepta Therapeutics already having approved drugs such as Exondys 51.
• PepGen's PGN-EDO51 is targeting the same exon 51 skipping as Exondys 51, but with a different delivery technology (EDO), which could potentially offer improved efficacy or safety.
• The safety profile reported for PGN-EDO51 appears favorable compared to some other oligonucleotide therapies, which have sometimes been associated with more significant adverse events.
• The development of therapies for DM1 is also an area of active research, with several companies exploring different approaches, including gene therapy and small molecules, making PepGen's oligonucleotide approach a notable contender.

Stakeholder Impact

• Shareholders may view the positive safety data and progress in clinical trials favorably.
• Patients with DMD and DM1 may be encouraged by the potential of these therapies.
• The scientific community will be interested in the data presented at the WMS Congress.
• Employees of PepGen may be motivated by the progress of the company's programs.

Next Steps

• The company will continue to advance the CONNECT1 study.
• The presentations will be made available on the Investors page of PepGen's website after the conference.

Key Dates

Keywords

PepGen, Duchenne muscular dystrophy, myotonic dystrophy type 1, PGN-EDO51, PGN-EDODM1, oligonucleotide therapies, World Muscle Society, clinical trial, exon skipping, neuromuscular diseases